← All trials
NCT02426112
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Oct 1, 2018
- Completion date
- Oct 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- Biomedical Research and Training Institute ZimbabweCollaborator
- Wellcome TrustCollaborator
- University of TromsoOverall official - principal investigator
- University of LondonOverall official - principal investigator
- University of TromsoCollaborator
- University of Cape TownCollaborator
- University of OxfordCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.